Mariana Gouveia

2026

• Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer

  Gouveia M, Freire P, Prado C, Leite C, Zucchetti B, Bonadio R, Barrios C, Kahn A, Lustberg M, Barroso-Sousa R. Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer. The Breast 2026, 89: 104853. PMID: 42398129, PMCID: PMC13355787, DOI: 10.1016/j.breast.2026.104853.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Altmetric

• American Society of Clinical Oncology annual meeting 2026: key clinical trial updates in gynecologic oncology

  de Melo M, Vasconcellos J, Gouveia M, Leis L, da Silva Neto A, de Mattos J, Scaranti M. American Society of Clinical Oncology annual meeting 2026: key clinical trial updates in gynecologic oncology. International Journal Of Gynecological Cancer 2026, 36: 104813. PMID: 42435735, DOI: 10.1016/j.ijgc.2026.104813.

  Commentaries, Editorials and Letters

  MeSH Keywords

• Early bird drinks fresh water: should chronoimmunotherapy be explored in gynecologic cancers?

  Miranda D, Gouveia M, Scaranti M. Early bird drinks fresh water: should chronoimmunotherapy be explored in gynecologic cancers? International Journal Of Gynecological Cancer 2026, 36: 104812. PMID: 42407136, DOI: 10.1016/j.ijgc.2026.104812.

  Commentaries, Editorials and Letters

• Expanding HER2-targeted therapeutic strategies in endometrial cancer

  Soares Pessoa B, Rathi K, Scaranti M, Gouveia M. Expanding HER2-targeted therapeutic strategies in endometrial cancer. International Journal Of Gynecological Cancer 2026, 36: 104792. PMID: 42341406, DOI: 10.1016/j.ijgc.2026.104792.

  Commentaries, Editorials and Letters

  Citations

• Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

  Tavares M, Balint F, Barroso-Sousa R, Testa L, Mandó P, Nunes N, Alejandro Mazzotta S, Rigesti M, M. Sousa I, O. Andrade M, Gouveia M, Madasi F, Bines J, D. P. Ferreira R, D. Rosa D, L. Santos C, R. Monteiro M, S. Souza Z, Assad-Suzuki D, H. dos Anjos C, M. Gagliato D, U. Gomes A, M. Zucchetti B, Ferrari A, L. Brito M, F. Monteiro M, Resende G, J. B. Gomes N, Costanzo M, Sanches S, Lima V, Casali Rocha J, Santana dos Santos E, B. Makdissi F, M. Hoff P, Estevez-Diz M, Colombo Bonadio R. Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort. Npj Breast Cancer 2026 PMID: 42230640, DOI: 10.1038/s41523-026-00966-5.

  Peer-Reviewed Original Research

• From congress to clinic: relevant trials presented at European Society of Gynaecological Oncology 2026

  Leis L, Vasconcellos J, Gouveia M, Melo M, da Silva Neto A, de Mattos J, Scaranti M. From congress to clinic: relevant trials presented at European Society of Gynaecological Oncology 2026. International Journal Of Gynecological Cancer 2026, 36: 104707. PMID: 42134101, DOI: 10.1016/j.ijgc.2026.104707.

  Commentaries, Editorials and Letters

  MeSH Keywords

• Beyond endocrine therapy: evolving treatment strategies in low-grade serous ovarian carcinoma

  Gouveia M, Zarzar Melo M, Vasconcellos J, Leis L, Scaranti M. Beyond endocrine therapy: evolving treatment strategies in low-grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2026, 36: 104699. PMID: 42070325, DOI: 10.1016/j.ijgc.2026.104699.

  Commentaries, Editorials and Letters

• Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review.

  Gouveia M, Shinkado Y, Pereira A, Feldmann J, Xavier E, Munhoz R, Scaranti M. Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review. Journal Of Immunotherapy 2026 PMID: 41944848, DOI: 10.1097/cji.0000000000000606.

  Peer-Reviewed Original Research

  Citations

• Breast cancer risk after ovarian cancer in patients with BRCA mutations: Implications in an era of improving survival

  Mattos J, Silva Neto A, Gouveia M, Kahn A, Scaranti M. Breast cancer risk after ovarian cancer in patients with BRCA mutations: Implications in an era of improving survival. International Journal Of Gynecological Cancer 2026, 36: 104672. PMID: 42001861, DOI: 10.1016/j.ijgc.2026.104672.

  Commentaries, Editorials and Letters

• Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis

  Noronha M, Gouveia M, de Almeida L, Silva L, Nohmi R, Passos P, Filho V, Al-Alam O, Saldanha E, Veneziani A. Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2026, 222: 105300. PMID: 41895358, DOI: 10.1016/j.critrevonc.2026.105300.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Citations

  MeSH Keywords